<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019302</url>
  </required_header>
  <id_info>
    <org_study_id>2015-07</org_study_id>
    <nct_id>NCT03019302</nct_id>
  </id_info>
  <brief_title>Arrow Chloragard Peripherally-Inserted Central Catheters (PICC) Study</brief_title>
  <official_title>A Study to Determine the Incidence of Catheter-Related Venous Thrombosis When Using Arrow Peripherally-Inserted Central Catheters With Chlorag+Ard Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teleflex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arrow International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Teleflex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study evaluating the timing, incidence and relationship of commonly occurring
      complications related to the use of peripherally-inserted central catheters. All subjects
      will receive PICC access using the Arrow PICC with Chloragard Technology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of symptomatic and asymptomatic catheter-related venous thrombosis (CVRT)</measure>
    <time_frame>within maximum 90 days dwell</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of catheter occlusion</measure>
    <time_frame>within maximum 90 days dwell</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of catheter-related bloodstream infections</measure>
    <time_frame>within maximum 90 days dwell</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vascular Access Complication</condition>
  <condition>Vascular Access Related Infection</condition>
  <arm_group>
    <arm_group_label>Arrow PICC with Chloragard Technology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arrow PICC with Chloragard Technology</intervention_name>
    <description>chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body</description>
    <arm_group_label>Arrow PICC with Chloragard Technology</arm_group_label>
    <other_name>Chloragard PICC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age ≥ 18 years requiring a PICC for a period of fourteen days or greater
             (note: maximum study period is 90 days)

          -  Ability to comply with study requirements inclusive of the follow-up duplex ultrasound
             procedures and, as applicable, recording of PICC management, interventions and related
             treatments in the inpatient and outpatient setting in the daily subject diary

          -  Patients cognitively and physically able to give written consent to participate in the
             study or patient has a legally authorized representative (LAR) who may give written
             consent to participate in the study

        Exclusion Criteria:

          -  Previous history of (within 3 months) or current diagnosis of venous thrombosis within
             the venous tract of the proposed catheter

          -  History or diagnosis of peripheral or central vein stenosis (on proposed insertion
             side)

          -  History or diagnosis of veno-occlusive disease

          -  History or diagnosis of superior vena cava syndrome

          -  Known, pre-existing diagnosis of hypercoagulation disorder unrelated to underlying
             disease

          -  Previous enrollment in this study

          -  Currently pregnant or breast feeding

          -  Previous axillary lymph node dissection on the same side as intended catheter
             insertion site unless cleared by physician and patient consent

          -  Skin condition at or within 15 cm of the proposed catheter insertion site, including
             signs and symptoms of inflammation, rash, crusts, wounds with drainage, sites of
             intravenous infusion infiltration or extravasation, hematoma, phlebitis and or
             thrombophlebitis

          -  Medical, social, and/or psychological problems precluding subject from study
             participation

          -  Stage 2, 3 or 4 chronic kidney disease or serum creatinine &gt; 3 mg/dl or Glomerular
             Filtration Rate (GFR) less than 60 mL per minute per 1.73 m2 unless cleared by a
             nephrologist for participation

          -  Known allergy or sensitivity to chlorhexidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatiana Puga</last_name>
    <email>tatiana.puga@teleflex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Philbeck, PhD</last_name>
    <email>thomas.philbeck@teleflex.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hossam Elbelasi, MD</last_name>
      <email>Hossam.Elbelasi@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Winkler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katee Dawood</last_name>
      <email>kdawood@wayne.edu</email>
    </contact>
    <investigator>
      <last_name>John Z Gallien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

